Phase II randomized study of salvage therapy comparing nilotinib with dasatinib in patients with imatinib-resistant chornic phase chronic myeloid leukemia (JALSG CML210R Study)

Trial Profile

Phase II randomized study of salvage therapy comparing nilotinib with dasatinib in patients with imatinib-resistant chornic phase chronic myeloid leukemia (JALSG CML210R Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Dasatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 12 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top